Guidance
Evidence-based recommendations on lenalidomide (Revlimid) for maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma in adults.
Is this guidance up to date?
Next review: 2024
Commercial arrangement
There is a simple discount patient access scheme for lenalidomide. Contact HTA_UKandI@celgene.com for details.
The use of lenalidomide as a maintenance treatment after an autologous stem cell transplant at a dosage of 10 mg per day on days 1 to 21 of a 28-day cycle is outside the terms of the marketing authorisation for lenalidomide. Consequently, the statutory funding requirement does not apply to this recommendation. NICE received a remit to appraise this dosage under Regulation 5 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013.
Guidance development process
How we develop NICE technology appraisal guidance
Your responsibility
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to take this guidance fully into account, alongside the individual needs, preferences and values of their patients. The application of the recommendations in this guidance is at the discretion of health professionals and their individual patients and do not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.
All problems (adverse events) related to a medicine or medical device used for treatment or in a procedure should be reported to the Medicines and Healthcare products Regulatory Agency using the Yellow Card Scheme.
Commissioners and/or providers have a responsibility to provide the funding required to enable the guidance to be applied when individual health professionals and their patients wish to use it, in accordance with the NHS Constitution. They should do so in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities.
Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible.